Clinical trial
Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis.
NCT05832515 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis.
- Lead sponsor
- St. Petersburg State Pavlov Medical University
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 1, 2020
- Completion date
- December 1, 2026
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.